Hong Kong’s Insilico sells cancer drug candidate in potential US$500 million deal

[ad_1] Insilico Medicine, a Hong Kong-based AI-driven drug discovery company that intends to list in Hong Kong after it unveiled an initial public offering plan (IPO) last year, has sold…

Trenchant Announces Strategic Investment in GNQ Insilico Inc.

[ad_1] Vancouver, British Columbia–(Newsfile Corp. – December 1, 2023) – Trenchant Capital Corp. (CSE: TCC) (the “Company“) is pleased to announce that it has entered into a strategic investment with…